Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2025 Financial Results on March 24, 2026

Core Insights - Fennec Pharmaceuticals Inc. will release its full year and fourth quarter 2025 financial results on March 24, 2026, before U.S. market opening [1] - A conference call and webcast will be held on the same day to discuss the financial and business results [1][2] Company Overview - Fennec Pharmaceuticals is focused on combating ototoxicity in cancer patients undergoing cisplatin-based chemotherapy [3] - The company is commercializing PEDMARK, which aims to reduce the risk of platinum-induced ototoxicity, and has received FDA approval in September 2022, European Commission approval in June 2023, and U.K. approval in October 2023 under the name PEDMARQSI [3] Licensing and Market Presence - In March 2024, Fennec entered an exclusive licensing agreement with Norgine Pharmaceuticals Ltd. for the commercialization of PEDMARQSI in Europe, U.K., Australia, and New Zealand [4] - PEDMARQSI is currently available in the U.K. and Germany [4] Regulatory Status and Protection - PEDMARK has received Orphan Drug Exclusivity in the U.S., and PEDMARQSI has received Pediatric Use Marketing Authorization in Europe, providing eight years plus two years of data and market protection [5] - Fennec holds patents for PEDMARK that extend protection until 2039 in both the U.S. and internationally [5]